Clinical Trial News and Research

RSS

InterMune reports new data from Esbriet clinical trial on IPF

InterMune, Inc. today reported that new data was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet(pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease.

26 Sep 2011

Percutaneous hepatic perfusion extends survival time for melanoma patients

Melanoma of the eye frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.

26 Sep 2011

Vaxent, PREVENT sign license agreement to develop and commercialize Strep-A vaccine

An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

Komen Foundation grant enables TGen scientists to study triple-negative breast cancer

The Translational Genomics Research Institute (TGen) is part of a team of medical investigators receiving a $3.5 million grant from Susan G. Komen for the Cure to study triple-negative breast cancer, a highly aggressive form of this cancer that disproportionately affects African-Americans.

26 Sep 2011

Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer

Men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone, according to results from a phase III clinical trial presented today.

26 Sep 2011

Breast cancer drug combination could stop cancer “in its tracks”

The results of a new study revealed that treatment for women with HER2-positive breast cancer – an aggressive form of the disease which is diagnosed in 10,000 British women each year – slowed the progression of tumors by 40 per cent compared with conventional drugs. Tests on 137 women showed that the new therapy – called T-DM1 – which combines the drug Herceptin with an antibody drug, instead of with standard chemotherapy, appeared to stop the cancer “in its tracks”.

26 Sep 2011

Drug combo for breast cancer in post-menopausal women shows promise

Combining two drugs in post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, a new study data showed.

26 Sep 2011

Zometa bone drug trial in post-menopausal women with breast cancer

Results from a latest large-scale clinical trial called Azure found that Novartis AG's bone drug Zometa extended survival in older breast cancer patients but failed to improve disease-free survival among younger women patients.

26 Sep 2011

Embryonic stem cell therapy for incurable Stargardt eye disease

...

26 Sep 2011

Combination of everolimus, exemestane holds promise against post-menopausal breast cancer

Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome.

26 Sep 2011

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced that treatment and follow-up have been completed on 69 patients in the Company's Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome, five more than the number of evaluable patients contemplated in the trial's protocol.

26 Sep 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011.

23 Sep 2011

Researchers to expand malaria vaccine study after initial trial yields encouraging results

Encouraged by early results of a study of an experimental malaria vaccine involving 45 children in Burkina Faso, researchers led by Pierre Druilhe at the Pasteur Institute in Paris are set to expand the clinical trial, resulting in a larger study involving 800 children in Mali, BBC News reports.

23 Sep 2011

SANUWAVE announces dermaPACE Phase III trial results on diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the Company's dermaPACE device will be the subject of a presentation at Plastic Surgery 2011, the American Society of Plastic Surgeons' National Meeting being held September 23-27 in Denver.

23 Sep 2011

Anti-obesity drug Contrave may get another chance to prove itself

With rise obesity around the world there should have been a number of drugs to combat it. The reality is different. There are no safe and effective drugs in the market at present.

22 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1.5 million from the Foundation Fighting Blindness to fund a pre-clinical trial evaluating the safety and efficacy of a gene therapy treatment for X-linked Retinoschisis (XLRS), a genetic eye disease affecting over 35,000 patients in the US and Europe.

22 Sep 2011

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt's Macular Dystrophy using retinal pigment epithelium (RPE) derived from human embryonic stem cells.

22 Sep 2011

Palatin's fourth quarter net loss decreases to $3.3 million

Palatin Technologies, Inc., a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.

22 Sep 2011

Clinical Trial News and Research

InterMune reports new data from Esbriet clinical trial on IPF

Percutaneous hepatic perfusion extends survival time for melanoma patients

Vaxent, PREVENT sign license agreement to develop and commercialize Strep-A vaccine

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Komen Foundation grant enables TGen scientists to study triple-negative breast cancer

Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer

Breast cancer drug combination could stop cancer “in its tracks”

Drug combo for breast cancer in post-menopausal women shows promise

Zometa bone drug trial in post-menopausal women with breast cancer

Embryonic stem cell therapy for incurable Stargardt eye disease

Combination of everolimus, exemestane holds promise against post-menopausal breast cancer

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

Researchers to expand malaria vaccine study after initial trial yields encouraging results

SANUWAVE announces dermaPACE Phase III trial results on diabetic foot ulcers

Anti-obesity drug Contrave may get another chance to prove itself

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Palatin's fourth quarter net loss decreases to $3.3 million

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery